The phrase "Research Use Only" appears on peptide product pages across the internet, usually without explanation. In many cases it is appended to marketing copy that simultaneously makes implicit or explicit claims about human health effects. Understanding the actual legal framework — and the obligations it creates for suppliers — matters whether you are a researcher, a purchaser, or a supplier operating in this space.
The UK regulatory framework
In the United Kingdom, the primary legislation governing medicinal products is the Medicines Act 1968, as substantially updated and supplemented by the Human Medicines Regulations 2012. Under this framework, a product becomes a "medicinal product" and subject to medicines regulation when it satisfies either of two tests: the presentation test, or the function test.
The presentation test is met when a product is presented as having properties for treating or preventing disease in humans. The function test is met when a product is intended to be administered to humans to restore, correct, or modify physiological functions, or to make a medical diagnosis. Both tests are applied independently — a product need only satisfy one to be regulated as a medicine.
How peptides fall outside medicines regulation
Research peptides sold under the RUO (Research Use Only) classification operate outside medicines regulation by satisfying neither test. They are not presented as having properties for treating disease in humans — no therapeutic claims are made. And they are not intended for administration to humans — they are supplied for in vitro (cell-based) or in vivo (animal model) laboratory research. The classification is legitimate provided these conditions are genuinely met.
The key principle is that the regulatory status of a compound is not determined by its molecular structure alone. The same compound could be regulated as a medicine in one context (if sold for human use with therapeutic claims) and unregulated as a medicine in another (if sold for laboratory research with no therapeutic claims). Context and presentation determine regulation — not chemistry.
What the RUO classification requires of suppliers
What RUO does not protect against
Research Use Only is not a blanket exemption from all regulation. The following continue to apply regardless of RUO classification: consumer protection law under the Consumer Rights Act 2015 and Consumer Protection from Unfair Trading Regulations 2008; trading standards requirements for accurate product description; general product safety law; and the Misuse of Drugs Act 1971 for any scheduled substances.
A supplier who labels a product "Research Use Only" while simultaneously selling it with dosing guides, before-and-after images, or language about body composition results is not operating within the RUO framework. The label does not alter the reality of what the product is being sold for. Regulators and courts assess the overall presentation, not just the disclaimer.
Controlled substances and scheduled compounds
Some peptides intersect with UK controlled substance law. The Psychoactive Substances Act 2016 applies to compounds that affect mental functioning or emotional state. Compounds that are analogues of scheduled substances may fall under the Misuse of Drugs Act. The RUO classification does not override these frameworks. Any supplier or researcher working with compounds in these categories must take independent legal advice on their specific situation.
The Nexapep position
All Nexapep products are labelled for laboratory research use only. Our product descriptions describe biochemical mechanisms studied in preclinical models — not personal health outcomes. We do not provide dosing guidance. We do not publish testimonials. We do not respond to enquiries seeking advice on personal use. This is not a legal formality. It is how we operate.